# Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes

> **NCT01910870** · PHASE2 · TERMINATED · sponsor: **Centre Jean Perrin** · enrollment: 4 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Metronomic Cyclophosphamide

## Key facts

- **NCT ID:** NCT01910870
- **Lead sponsor:** Centre Jean Perrin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-07
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Because of difficulties in recruiting
- **Last updated:** 2018-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01910870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01910870, "Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01910870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*